281 related articles for article (PubMed ID: 21831227)
41. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
[TBL] [Abstract][Full Text] [Related]
42. [Desensitization protocols in immunized living donor kidney transplant recipients].
Nocera A
G Ital Nefrol; 2009; 26(4):499-515. PubMed ID: 19644839
[TBL] [Abstract][Full Text] [Related]
43. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
Fehr T; Gaspert A
Transpl Int; 2012 Jun; 25(6):623-32. PubMed ID: 22394269
[TBL] [Abstract][Full Text] [Related]
44. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
45. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
[TBL] [Abstract][Full Text] [Related]
46. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
[TBL] [Abstract][Full Text] [Related]
47. Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients.
Montgomery RA; Lonze BE; Jackson AM
Curr Opin Organ Transplant; 2011 Aug; 16(4):439-43. PubMed ID: 21666478
[TBL] [Abstract][Full Text] [Related]
48. Sensitized renal transplant recipients: current protocols and future directions.
Gloor J; Stegall MD
Nat Rev Nephrol; 2010 May; 6(5):297-306. PubMed ID: 20234355
[TBL] [Abstract][Full Text] [Related]
49. Posttransplant immunosuppression in highly sensitized patients.
Akalin E
Contrib Nephrol; 2009; 162():27-34. PubMed ID: 19001811
[TBL] [Abstract][Full Text] [Related]
50. [HLA-incompatibility and kidney transplant: a question of desensitization].
Grosjean F
G Ital Nefrol; 2011; 28(6):581. PubMed ID: 22167608
[No Abstract] [Full Text] [Related]
51. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
[TBL] [Abstract][Full Text] [Related]
52. Luminex-based desensitization protocols: the University of Wisconsin initial experience.
Niederhaus SV; Muth B; Lorentzen DF; Wai P; Pirsch JD; Samaniego-Picota M; Leverson GE; D'alessandro AM; Sollinger HW; Djamali A
Transplantation; 2011 Jul; 92(1):12-7. PubMed ID: 21512428
[TBL] [Abstract][Full Text] [Related]
53. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient.
Chehade H; Rotman S; Matter M; Girardin E; Aubert V; Pascual M
Pediatrics; 2015 Feb; 135(2):e551-5. PubMed ID: 25624380
[TBL] [Abstract][Full Text] [Related]
54. Current approaches to treatment of antibody-mediated rejection.
Jordan SC; Vo AA; Tyan D; Nast CC; Toyoda M
Pediatr Transplant; 2005 Jun; 9(3):408-15. PubMed ID: 15910400
[TBL] [Abstract][Full Text] [Related]
55. A case of severe C4d-positive kidney allograft dysfunction in the absence of histomorphologic features of rejection.
Habicht A; Regele H; Exner M; Soleiman A; Hörl WH; Watschinger B; Derfler K; Böhmig GA
Wien Klin Wochenschr; 2002 Nov; 114(21-22):945-8. PubMed ID: 12528329
[TBL] [Abstract][Full Text] [Related]
56. Antibody-mediated rejection of renal allograft in combined liver-kidney transplant.
Barth RN; Campos L; Kukuruga DL; Drachenberg C; Philosophe B
Clin Transplant; 2010; 24(5):685-90. PubMed ID: 19925465
[TBL] [Abstract][Full Text] [Related]
57. Proteasome inhibitor-based therapy for antibody-mediated rejection.
Walsh RC; Alloway RR; Girnita AL; Woodle ES
Kidney Int; 2012 Jun; 81(11):1067-74. PubMed ID: 22336990
[TBL] [Abstract][Full Text] [Related]
58. Desensitization strategies enabling successful renal transplantation in highly sensitized patients.
Beimler JH; Susal C; Zeier M
Clin Transplant; 2006; 20 Suppl 17():7-12. PubMed ID: 17100695
[TBL] [Abstract][Full Text] [Related]
59. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.
Lefaucheur C; Suberbielle-Boissel C; Hill GS; Nochy D; Andrade J; Antoine C; Gautreau C; Charron D; Glotz D
Contrib Nephrol; 2009; 162():1-12. PubMed ID: 19001809
[TBL] [Abstract][Full Text] [Related]
60. Modifiers of complement activation for prevention of antibody-mediated injury to allografts.
Hughes PD; Cohney SJ
Curr Opin Organ Transplant; 2011 Aug; 16(4):425-33. PubMed ID: 21681097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
